+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Advanced Renal Cell Carcinoma - Pipeline Insight, 2021

  • ID: 5416110
  • Drug Pipelines
  • September 2021
  • Region: Global
  • 60 Pages
  • DelveInsight
UP TO OFF
until Dec 31st 2021

FEATURED COMPANIES

  • Allogene Therapeutics
  • Apollomics
  • Astex Pharmaceuticals
  • Daiichi Sankyo, Inc.
  • MedImmune LLC
  • Roche
This Advanced Renal Cell Carcinoma - Pipeline Insight, 2021 report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Advanced Renal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Advanced Renal Cell Carcinoma: Overview


Renal cell carcinoma is the most common type of kidney cancer. It usually starts as a tumor in one of your kidneys. And like other cancers, it can spread to other parts of your body. That's when doctors call it metastatic. As the tumor grows, it spreads into fat or major blood vessels around the kidney. It may also creep into the adrenal gland, which sits right on top of the organ. Kidney cancer most often spreads to the lungs and bones, but it can also go to the brain, liver, ovaries, and testicles. The process used to find out if cancer has spread within the kidney or to other parts of the body is called staging. The information gathered from the staging process determines the stage of the disease. It is important to know the stage in order to plan treatment. The following tests and procedures may be used in the staging process: CT scan; MRI (magnetic resonance imaging); Chest x-ray; and bone scan. Different types of treatments are available for patients with renal cell cancer. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials.

"Advanced Renal Cell Carcinoma - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Renal Cell Carcinoma pipeline landscape is provided which includes the disease overview and Advanced Renal Cell Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Advanced Renal Cell Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Renal Cell Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Renal Cell Carcinoma.

Advanced Renal Cell Carcinoma Understanding

Advanced Renal Cell Carcinoma Emerging Drugs Chapters


This segment of the Advanced Renal Cell Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Renal Cell Carcinoma Emerging Drugs


Atezolizumab: Roche


Atezolizumab is a humanized monoclonal antibody immune checkpoint inhibitor that selectively binds to PD-L1 to stop the interaction between PD-1 and B7. 1 (ie, CD80 receptors). The antibody still allows interaction between PD-L2 and PD-1. Currently, it is in Phase III stage of clinical trial evaluation to treat advanced Renal Cell Carcinoma.

Bempegaldesleukin (NKTR-214): Nektar Therapeutics


Bempegaldesleukin is a CD122-preferential IL-2 pathway agonist designed to stimulate the patient's own immune system to fight cancer. Bempegaldesleukin is designed to grow specific cancer-killing T cells and natural killer (NK) cell populations in the body which fight cancer, which are known as endogenous tumor-infiltrating lymphocytes (TILs). Bempegaldesleukin stimulates these cancer-killing immune cells in the body by targeting CD122 specific receptors found on the surface of these immune cells, known as CD8+ effector T cells and NK cells. CD122, which is also known as the Interleukin-2 receptor beta subunit, is a key signaling receptor that is known to increase proliferation of these effector T cells. In clinical and preclinical studies, treatment with bempegaldesleukin resulted in expansion of these cells and mobilization into the tumor micro-environment. Bempegaldesleukin has an antibody-like dosing regimen similar to the existing checkpoint inhibitor class of approved medicines.

Advanced Renal Cell Carcinoma: Therapeutic Assessment


This segment of the report provides insights about the different Advanced Renal Cell Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Advanced Renal Cell Carcinoma


There are approx. 40+ key companies which are developing the therapies for Advanced Renal Cell Carcinoma. The companies which have their Advanced Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Roche.

Phases


This report covers around 40+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Advanced Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced Renal Cell Carcinoma: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Renal Cell Carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Renal Cell Carcinoma drugs.

Advanced Renal Cell Carcinoma Report Insights

  • Advanced Renal Cell Carcinoma Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Advanced Renal Cell Carcinoma Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Advanced Renal Cell Carcinoma drugs?
  • How many Advanced Renal Cell Carcinoma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Renal Cell Carcinoma?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Advanced Renal Cell Carcinoma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Advanced Renal Cell Carcinoma and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Roche
  • Nektar Therapeutic
  • MedImmune LLC
  • CoImmune
  • X4 Pharmaceuticals
  • Daiichi Sankyo, Inc.
  • Eli Lilly and Company
  • Jiangsu HengRui Medicine Co., Ltd.
  • Allogene Therapeutics
  • Apexigen, Inc.
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Aravive, Inc.
  • Arrowhead Pharmaceuticals
  • Merck
  • Apollomics
  • Astex Pharmaceuticals
  • Peloton Therapeutics, Inc.
  • Infinity Pharmaceuticals
  • Surface Oncology
  • AO GENERIUM
  • CRISPR Therapeutics AG

Key Products

  • Atezolizumab
  • Bempegaldesleukin
  • MEDI5752
  • CMN-001
  • X4P-001
  • PT2385
  • GNR-051
  • CTX130
  • Guadecitabine
  • SRF388
  • ARO-HIF2
  • DS-6000a
  • Abemaciclib
  • SHR-1210
  • ALLO-316
  • APX005M
  • TQB2450
  • AVB-S6-500
  • APL-501
  • IPI-549
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allogene Therapeutics
  • Apollomics
  • Astex Pharmaceuticals
  • Daiichi Sankyo, Inc.
  • MedImmune LLC
  • Roche
Introduction

Executive Summary

Advanced Renal Cell Carcinoma: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Advanced Renal Cell Carcinoma - Analytical Perspective

Late Stage Products (Phase III)
  • Comparative Analysis
Atezolizumab: Roche
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Guadecitabine: Astex Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
MEDI5752: MedImmune
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Advanced Renal Cell Carcinoma Key Companies

Advanced Renal Cell Carcinoma Key Products

Advanced Renal Cell Carcinoma- Unmet Needs

Advanced Renal Cell Carcinoma- Market Drivers and Barriers

Advanced Renal Cell Carcinoma- Future Perspectives and Conclusion

Advanced Renal Cell Carcinoma Analyst Views

Advanced Renal Cell Carcinoma Key Companies

Appendix
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Roche
  • Nektar Therapeutic
  • MedImmune LLC
  • CoImmune
  • X4 Pharmaceuticals
  • Daiichi Sankyo, Inc.
  • Eli Lilly and Company
  • Jiangsu HengRui Medicine Co., Ltd.
  • Allogene Therapeutics
  • Apexigen, Inc.
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Aravive, Inc.
  • Arrowhead Pharmaceuticals
  • Merck
  • Apollomics
  • Astex Pharmaceuticals
  • Peloton Therapeutics, Inc.
  • Infinity Pharmaceuticals
  • Surface Oncology
  • AO GENERIUM
  • CRISPR Therapeutics AG
Note: Product cover images may vary from those shown
Adroll
adroll